There are two main types of lung cancer: small cell and non-small cell. According to the American Cancer Society, non-small ...

Genprex has dosed the first subject in the Phase II expansion portion of its Acclaim-3 trial of the Reqorsa gene therapy ...

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

Genprex (GNPX) announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the company’s Acclaim-3 ...

The NSCLC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...

Ultrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...